|
Identifying trends for high symptom burden across the care continuum in adolescents and young adults (AYA) with hematologic malignancies. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Adaptive Biotechnologies; agios; GlaxoSmithKline; Jazz Pharmaceuticals; Kite, a Gilead company; Kura Oncology; morphosys; Pfizer; SERVIER |
Patents, Royalties, Other Intellectual Property - Royalties for a chapter in Up to Date |
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Jazz Pharmaceuticals |
|
|
Other Relationship - Seagen |
(OPTIONAL) Uncompensated Relationships - National Academies of Medicine, Engineering and Sciences Committee on Disability and Childhood Cancer |
|
|
Consulting or Advisory Role - Daiichi Sankyo; Sun Pharma |